AbbVie To Participate In Federal 340b Rebate Model Pilot
https://news.abbvie.com/2026-10-02-AbbVie-to-Participate-in-Federal-340B-Rebate-Model-Pilot
Stocks · News reference
UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses
UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8 Of 11 Sectors Rise Friday As Growth Leads
Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.
AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress
AbbVie Stock: Buy, Sell, or Hold in October?
AbbVie, a pharmaceutical giant with 53 consecutive years of dividend increases, remains a stable long-term investment despite losing U.S. patent exclusivity for its blockbuster drug Humira in 2023. The company has offset this decline through new immunology drugs (Skyrizi and Rinvoq) and strategic acquisitions including Allergan (Botox). Analysts project 9% revenue CAGR and 21% adjusted EPS CAGR from 2025-2028. At $264 per share with a 2.6% forward yield and 16x forward P/E, the stock is reasonably valued for buy-and-hold investors.
Piper Sandler Maintains Overweight on Cigna Group, Raises Price Target to $370
Piper Sandler analyst Jessica Tassan maintains Cigna Group (NYSE:CI) with a Overweight and raises the price target from $346 to $370.
RBC Capital Reiterates Outperform on Cigna Group, Maintains $337 Price Target